[go: up one dir, main page]

CY1105795T1 - Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων - Google Patents

Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων

Info

Publication number
CY1105795T1
CY1105795T1 CY20061101680T CY061101680T CY1105795T1 CY 1105795 T1 CY1105795 T1 CY 1105795T1 CY 20061101680 T CY20061101680 T CY 20061101680T CY 061101680 T CY061101680 T CY 061101680T CY 1105795 T1 CY1105795 T1 CY 1105795T1
Authority
CY
Cyprus
Prior art keywords
orally administered
bioavailability
formulations
improving
administered drugs
Prior art date
Application number
CY20061101680T
Other languages
English (en)
Inventor
Johannes Henricus Matthias Schellens
Alfred Hermanus Schinkel
Original Assignee
Cancer Research Ventures Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Ventures Limited filed Critical Cancer Research Ventures Limited
Publication of CY1105795T1 publication Critical patent/CY1105795T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Μια μέθοδος αύξησης της συστηματικής έκθεσης κυττάρων που επιλέγονται από καρκινικά κύτταρα και φυσιολογικά κύτταρα σε μια χορηγούμενη από το στόμα φαρμακευτικώς δραστική ένωση, όπου ένας βιοενισχυτής που περιέχει έναν αναστολέα της προκαλούμενης από και/ή σχετιζόμενης με BCRP μεταφοράς φαρμάκων χορηγείται από το στόμα συγχρόνως με την αναφερόμενη χορηγούμενη από το στόμα φαρμακευτικώς δραστική ένωση, και στην οποία μέθοδο ο αναστολέας χορηγείται συγχρόνως με την φαρμακευτική ένωση.
CY20061101680T 1999-05-17 2006-11-16 Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων CY1105795T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL1012066 1999-05-17
NL1012481 1999-06-30
PCT/NL2000/000331 WO2000069390A2 (en) 1999-05-17 2000-05-17 Compositions for improving bioavailability of orally administered drugs

Publications (1)

Publication Number Publication Date
CY1105795T1 true CY1105795T1 (el) 2011-02-02

Family

ID=26642978

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101680T CY1105795T1 (el) 1999-05-17 2006-11-16 Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων

Country Status (10)

Country Link
US (2) US7030132B2 (el)
EP (2) EP1189637B1 (el)
AT (2) ATE484295T1 (el)
AU (1) AU4955200A (el)
CY (1) CY1105795T1 (el)
DE (2) DE60045114D1 (el)
DK (1) DK1189637T3 (el)
ES (1) ES2270834T3 (el)
PT (1) PT1189637E (el)
WO (1) WO2000069390A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
PT1189637E (pt) * 1999-05-17 2007-01-31 Cancer Res Ventures Ltd Composições para melhorar a biodisponibilidade de fármacos administrados oralmente
HU0100947D0 (en) * 2001-03-02 2001-05-28 Solvo Kft Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
US20080312250A1 (en) * 2004-07-01 2008-12-18 The Netherlands Cancer Institute Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide
US8518022B2 (en) 2004-08-27 2013-08-27 Medimetrics Personalized Drug Delivery, Inc. Electronically and remotely controlled pill and system for delivering at least one medicament
CN101065161B (zh) * 2004-11-29 2013-03-13 皇家飞利浦电子股份有限公司 电子可控药丸
WO2006065125A1 (en) * 2004-12-16 2006-06-22 Het Nederlands Kanter Instituut Means and methods for determining and/or influencing transportation
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
US20100331827A1 (en) * 2008-02-18 2010-12-30 Koninklijke Philips Electronics N.V. Administration of drugs to a patient
JP5681861B2 (ja) * 2008-03-31 2015-03-11 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ センサを有する嚥下型カプセルを作成する方法
CA2722858C (en) 2008-04-30 2017-08-29 Siemens Medical Solutions Usa, Inc. Substrate based pet imaging agents
US9067011B2 (en) * 2008-06-19 2015-06-30 MEDIMETRICS Personalized Drug Delivery B.V. Device for delivery of powder like medication in a humid environment
CN102076375B (zh) * 2008-06-25 2013-11-20 皇家飞利浦电子股份有限公司 包括多个药物储存器的电子药丸
JP5497176B2 (ja) 2009-08-12 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 圧縮可能な薬品貯槽を備える薬品送出装置
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201084A (en) 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such
EP0569380B1 (en) * 1991-01-11 1997-05-28 Laboratoires Glaxo Sa Acridine derivatives
DK0649410T3 (da) 1992-07-10 1997-09-15 Glaxo Lab Sa Anilidderivater.
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
PL319511A1 (en) 1994-10-05 1997-08-18 Glaxo Wellcome Inc Parenteral pharmaceutic compositions containing gf120918a
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
AU7130098A (en) 1995-10-26 1998-12-30 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6313277B1 (en) * 1998-02-05 2001-11-06 University Of Maryland, Baltimore Breast cancer resistance protein (BCRP) and the DNA which encodes it
AU764370B2 (en) 1998-06-18 2003-08-14 George Washington University, The Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
US6476043B1 (en) 1998-08-05 2002-11-05 Aventis Pharma S.A. Use of camptothecin derivatives, with reduced gastrointestinal toxicity
PT1189637E (pt) * 1999-05-17 2007-01-31 Cancer Res Ventures Ltd Composições para melhorar a biodisponibilidade de fármacos administrados oralmente
US6521635B1 (en) * 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives

Also Published As

Publication number Publication date
DE60030283D1 (de) 2006-10-05
DE60030283T2 (de) 2007-09-20
WO2000069390A3 (en) 2001-12-13
EP1749540B1 (en) 2010-10-13
DE60045114D1 (de) 2010-11-25
WO2000069390A2 (en) 2000-11-23
ATE337016T1 (de) 2006-09-15
US20060128743A1 (en) 2006-06-15
US7030132B2 (en) 2006-04-18
AU4955200A (en) 2000-12-05
EP1749540A3 (en) 2007-05-30
ES2270834T3 (es) 2007-04-16
US20020128282A1 (en) 2002-09-12
EP1189637B1 (en) 2006-08-23
PT1189637E (pt) 2007-01-31
DK1189637T3 (da) 2006-12-11
EP1749540A2 (en) 2007-02-07
ATE484295T1 (de) 2010-10-15
EP1189637A2 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
CY1105795T1 (el) Σκευασματα για βελτιωση της βιοδιαθεσιμοτητας χορηγουμενων απο το στομα φαρμακων
CY1118873T1 (el) Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης
CY1106072T1 (el) Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος
TR200102226T2 (tr) Formoterol ve bir tiotropium tuzunun kombinasyonları
CY1112562T1 (el) Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
CY1117470T1 (el) Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
DE60137960D1 (de) Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
TR199800631A2 (xx) Ecza form�lasyonu.
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
ATE292453T1 (de) Antivirale arznei
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
TR199800765T2 (xx) Otoim�n hastal�klar�n tedavisine mahsus bir farmas�tik bile�im
EA200701409A1 (ru) Новая композиция
ES2188513T3 (es) Utilizacion de desoxipeganina para el tratamiento de la drogodependencia.
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
ATE306941T1 (de) Gesteigerte abgabe von auf nukleinsäuren basierenden arzneimitteln
SE9902742D0 (sv) New pharmaceutical formultion